Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT02453594Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co.. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02453594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453594.